Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genzyme’s Campath MS Safety Profile Expected From FDA By July; Phase III Set For Second Half

This article was originally published in The Pink Sheet Daily

Executive Summary

The firm expects to re-start a Phase II trial of alemtusumab in multiple sclerosis patients that was halted in 2005.

You may also be interested in...



Genzyme/Bayer Report Positive Top-Line Phase II MS Data For Campath

Clinical hold on the Phase II trial was lifted “within the last six months” and dosing completed, Genzyme’s Enyedy says.

Genzyme/Bayer Report Positive Top-Line Phase II MS Data For Campath

Clinical hold on the Phase II trial was lifted “within the last six months” and dosing completed, Genzyme’s Enyedy says.

Genzyme Reports Interim Data From Troubled Campath Study

Multiple sclerosis therapy meets efficacy endpoints, but safety issues remain.

Related Content

Topics

UsernamePublicRestriction

Register

IV001392

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel